Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094658 | 0.75 | POLG (0.41) | POLGPOLBFGFR1SLC22A6POLA1 | |
| SCHEMBL1144357 | 0.75 | POLG (0.44) | POLGPOLBFGFR1SLC22A6POLA1 | |
| SCHEMBL1629582 | 0.75 | FGFR1 (0.44) | POLGPOLBFGFR1SLC22A6POLA1 | |
| SCHEMBL6402546 | 0.74 | TSHR (0.65) | TSHRGLAP2RY2 | |
| SCHEMBL76047 | 0.73 | POLG (0.47) | POLGPOLBFGFR1SLC22A6P2RY2 | |
| SCHEMBL10496372 | 0.73 | POLG (0.47) | POLGPOLBFGFR1SLC22A6P2RY2 | |
| SCHEMBL26123976 | 0.72 | POLG (0.47) | POLGPOLBFGFR1SLC22A6P2RY2 | |
| SCHEMBL760215 | 0.71 | TSHR (0.68) | TSHRGLAP2RY2 | |
| SCHEMBL14125515 | 0.71 | P2RY2 (0.62) | TSHRGLAP2RY2 | |
| SCHEMBL27689266 | 0.71 | FGFR1 (0.47) | POLGPOLBTSHRFGFR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269160-A1 | Use Of Citicoline In Regulating Respiratory Chain Function Related Protein Level And Preparing Drug For Preventing And Treating Respiratory Chain Dysfunction | TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-208700933-U | A kind of phosphoryl chloride choline calcium salt crystal system | 如皋市众昌化工有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-109160932-A | One kind 11/2Water Citicoline sodium compound and its drug combination preparation | 刘兆娟 | 2019-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269160-A1 | Use Of Citicoline In Regulating Respiratory Chain Function Related Protein Level And Preparing Drug For Preventing And Treating Respiratory Chain Dysfunction | PCYT1A, CHRNA1, CPT1B | POLG 1488/4885POLB 850/4885TSHR 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.